Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia

Wyeth

Status and phase

Terminated

Phase 2

Conditions

Arrhythmias

Treatments

Drug: GAP-486

Drug: Double-blind investigational anti-arrhythmic

Study type

Interventional

Funder types

Industry

Identifiers

NCT00124891

3163K1-200

Details and patient eligibility

About

To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female patients, 18 years of age or older, that have experienced an acute ischemic event within 24 hours prior to study entry.
Patients with a documented history of coronary artery disease or left ventricular dysfunction
Patients who have experienced an episode of non-sustained ventricular tachycardia within 24 hours of the index ischemic event

Exclusion criteria

Patients who have had percutaneous coronary intervention (PCI), thrombolytics, or open-heart surgery within 48 hours prior to study entry, or who require it during test article administration
Patients who have taken another antiarrhythmic medication (other than a beta blocker) within 5 half-lives of the start of test article
Patients who have a history of torsades de pointes, long QT syndrome, QTc > 0.50